MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models

14:31 EDT 24 May 2018 | Nature Publishing

More From BioPortfolio on "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models"